Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia-Reference-Cited by-同舟云学术

Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia

Published:2019-10-16 Issue:20 Volume:3 Page:2911-2919
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Winters Amanda C.¹^ORCID,Gutman Jonathan A.²,Purev Enkhtsetseg²,Nakic Molly³,Tobin Jennifer⁴,Chase Stephanie⁴,Kaiser Jeff⁴,Lyle Lindsey²,Boggs Chelsey²,Halsema Keri²,Schowinsky Jeffrey T.⁵,Rosser Julie⁵,Ewalt Mark D.⁵^ORCID,Siegele Bradford⁵,Rana Vishal⁶,Schuster Steven⁷,Abbott Diana⁸^ORCID,Stevens Brett M.²,Jordan Craig T.²,Smith Clayton²,Pollyea Daniel A.²

Affiliation:

1. Center for Cancer and Blood Disorders, Department of Pediatrics, University of Colorado Denver, Aurora, CO;

2. Division of Hematology, Department of Medicine, University of Colorado, Aurora, CO;

3. University of Colorado Hospital, Aurora, CO;

4. Skaggs School of Pharmacy and

5. Department of Pathology, University of Colorado Denver, Aurora, CO;

6. University of Colorado Hospital, Colorado Springs, CO;

7. University of Colorado Hospital, Fort Collins, CO; and

8. Center for Innovative Design and Analysis, Department of Biostatistics and Informatics, University of Colorado Denver, Aurora, CO

Abstract

Key Points Responses and survival with venetoclax for “real-world” AML patients were promising but inferior to those treated in a clinical trial. Compared with induction, response rates are as high as would be predicted and venetoclax patients had a lower than expected early death rate.

Publisher

American Society of Hematology

Subject

Hematology

Link

http://ashpublications.org/bloodadvances/article-pdf/3/20/2911/1248603/advancesadv2019000243.pdf

Reference20 articles.

1. Long-term survival in acute myeloid leukemia: the Eastern Cooperative Oncology Group experience;Bennett;Cancer,1997

3. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts;Dombret;Blood,2015

4. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia;Kantarjian;J Clin Oncol,2012

Cited by 120 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Relapse and resistance in acute myeloid leukemia post venetoclax: improving second lines therapy and combinations;Expert Review of Hematology;2024-09-13

2. Real-world outcomes of newly diagnosed AML treated with venetoclax and azacitidine or low-dose cytarabine in the UK NHS;Blood Neoplasia;2024-09

3. Clinical management of patients diagnosed with acute myeloid leukemia treated with venetoclax in combination with hypomethylating agents after achieving a response: a real-life study;Annals of Hematology;2024-08-29

4. A systematic review of venetoclax for the treatment of unfit AML patients in real-world: is all that glitters gold?;Annals of Hematology;2024-08-16

5. In silico predicted compound targeting the IQGAP1-GRD domain selectively inhibits growth of human acute myeloid leukemia;Scientific Reports;2024-06-04